Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.59 (market cap $39.89B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $244.75 (market cap $45.15B). The key difference: Alnylam Pharmaceuticals, Inc. and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock are close in size by market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TTWO | |
|---|---|---|
Market Cap | $39.89B | $45.15B |
Sector | Health | Media |
52-Week High | $491.22 | $262.29 |
52-Week Low | $278.09 | $189.69 |
Enterprise Value | $38.15B | $46.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Take-Two Interactive (TTWO) trades at $243.20, down 1.18% on the day, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, including Q1 2026 EPS of $0.80 versus $0.563 expected, and benefits from positive sentiment around Grand Theft Auto VI pre-orders. However, fundamentals reveal challenges with a net income margin of -4.48% and negative ROE of -10.56%, though revenue grew to $5.63B in 2025. Cash flow improved with net cash flow of $457.20M in 2025, driven by financing activities.
The outlook is optimistic due to GTA VI's upcoming launch, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, with debt-to-asset ratio at 39.87% in 2025, and reliance on blockbuster game success. Institutional sentiment is strongly bullish, with 79% of analysts rating Buy, but investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
